AVLX-144
Acute Ischemic Stroke, Subarachnoid Hemorrhage
Phase 2Active
Key Facts
Indication
Acute Ischemic Stroke, Subarachnoid Hemorrhage
Phase
Phase 2
Status
Active
Company
About Avilex Pharma
Avilex Pharma is a Danish private biotech advancing a pipeline of neuroprotectants targeting PSD-95, a clinically validated target for acute brain injury. The company's lead asset, AVLX-144, has successfully cleared a Phase 1 safety trial and is poised for Phase 2 development in stroke-related indications, supported by venture capital and strategic partnerships. Avilex is also developing next-generation PSD-95 inhibitors and a companion diagnostic PET tracer, positioning it in the high-need, underserved neuroprotection market. The company leverages academic roots from the University of Copenhagen and has secured non-dilutive funding from prestigious grants.
View full company profile